The first prospective, randomized controlled trial of anti-cytokine therapy (infliximab) for depression treatment identified that TNF antagonism was effective at improving depressive symptoms only in patients with high inflammation11, although these results recently failed to be replicated in a cohort of bipolar patients42. The gene discussed is TNF; the disease is depressive symptom measurement.